Tafamidis Meglumine Soft not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Transthyretin Amyloid Polyneuropathy
- Main trialPhase 4
- “The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy”In the company’s words, NCT06940336 on ClinicalTrials.gov
Other drugs for Transthyretin Amyloid Polyneuropathy
- NTLA-2001Intellia Therapeutics · Phase 3
- AcoramidisEidos Therapeutics, a BridgeBio company · Marketed (Phase 4 trial)
Coming up1
- Jan 2028Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Jan 2028 | To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026